Telix Pharmaceuticals Limited Stock Performance

TLX Stock   18.30  0.06  0.33%   
On a scale of 0 to 100, Telix Pharmaceuticals holds a performance score of 5. The entity has a beta of 0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Telix Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telix Pharmaceuticals is expected to be smaller as well. Please check Telix Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Telix Pharmaceuticals' existing price patterns will revert.

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile essential indicators, Telix Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(0.65)
Five Day Return
(2.39)
Year To Date Return
22.4
Ten Year Return
21.19
All Time Return
21.19
1
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics ...
01/30/2025
2
Telix 2024 Full Year Results Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to 1.23 Billion
02/20/2025
3
Recruitment Spotlight Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
02/25/2025
4
Investor Webinar Telix Therapeutics Urology Showcase and Expert Forum
03/03/2025
5
Health Check Half-price sale as brokers ring the bell on Neuren shares
03/04/2025
6
Acquisition by Liss Victor S of tradable shares of Telix Pharmaceuticals at 9.0 subject to Rule 16b-3
03/07/2025
7
Up 136 percent in a year, why is this ASX 200 share slipping on Wednesday
03/11/2025
8
Illuccix Approved for Prostate Cancer Imaging in BrazilFirst
03/17/2025
9
Health Check Fantastico Telix wins Brazilian assent for prostate cancer imaging agent
03/18/2025
10
FDA Approves New Prostate Cancer Imaging Agent Gozellix
03/21/2025
11
Health Check Optheas solvency in question after monumental phase III eye disease trial failure
03/24/2025
Begin Period Cash Flow123.2 M
  

Telix Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  1,646  in Telix Pharmaceuticals Limited on December 26, 2024 and sell it today you would earn a total of  184.00  from holding Telix Pharmaceuticals Limited or generate 11.18% return on investment over 90 days. Telix Pharmaceuticals Limited is generating 0.2255% of daily returns assuming volatility of 3.2666% on return distribution over 90 days investment horizon. In other words, 29% of stocks are less volatile than Telix, and above 96% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon Telix Pharmaceuticals is expected to generate 3.81 times more return on investment than the market. However, the company is 3.81 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.03 per unit of risk.

Telix Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telix Pharmaceuticals Limited, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.069

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsTLX
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.27
  actual daily
29
71% of assets are more volatile

Expected Return

 0.23
  actual daily
4
96% of assets have higher returns

Risk-Adjusted Return

 0.07
  actual daily
5
95% of assets perform better
Based on monthly moving average Telix Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding it to a well-diversified portfolio.

Telix Pharmaceuticals Fundamentals Growth

Telix Stock prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Stock performance.

About Telix Pharmaceuticals Performance

Evaluating Telix Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 50.90  65.25 
Return On Tangible Assets 0.05  0.05 
Return On Capital Employed 0.07  0.07 
Return On Assets 0.03  0.03 
Return On Equity 0.09  0.09 

Things to note about Telix Pharmaceuticals performance evaluation

Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Telix Pharmaceuticals had very high historical volatility over the last 90 days
Telix Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Telix Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from stockhead.com.au: Health Check Optheas solvency in question after monumental phase III eye disease trial failure
Evaluating Telix Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Telix Pharmaceuticals' stock performance include:
  • Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' stock. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Telix Pharmaceuticals' stock performance is not an exact science, and many factors can impact Telix Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.